Advertisement
Advertisement
ALLO
Allogene Therapeutics, Inc. Common Stock
1.67
USDSponsored
-0.04
-2.34%
Sep 23, 15:42 UTC -4
Closed
After-Market
1.71
+0.04
+2.10%
ALLO Earnings Reports
Positive Surprise Ratio
ALLO beat 29 of 32 last estimates.
91%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.26K
/-$0.15
Implied change from Q2 26 (Revenue/ EPS)
-99.95%
/+15.38%
Implied change from Q3 25 (Revenue/ EPS)
--
/-21.05%
Allogene Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, ALLO reported earnings of -0.13 USD per share (EPS) for Q2 26, beating the estimate of -0.17 USD, resulting in a 25.50% surprise. Revenue reached 4.64 million, compared to an expected 2.26 thousand, with a 204847.00% difference. The market reacted with a -4.35% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 2.26 thousand USD, implying an increase of 15.38% EPS, and decrease of -99.95% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Allogene Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Allogene Therapeutics, Inc. Common Stock reported EPS of -$0.13, beating estimates by 25.5%, and revenue of $4.64M, 204847% above expectations.
How did the market react to Allogene Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -4.35%, changed from $2.07 before the earnings release to $1.98 the day after.
When is Allogene Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Allogene Therapeutics, Inc. Common Stock's next earnings report?
Based on 12
analysts, Allogene Therapeutics, Inc. Common Stock is expected to report EPS of -$0.15 and revenue of $2.26K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.